Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | GUCY1A1 | Q02108 | 19/20 | 0.44 |
| ▸ | GUCY1B1 | Q02153 | 19/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21413147 | 0.90 | KDM4C (0.41) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL18999258 | 0.88 | KMO (0.42) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL15117031 | 0.87 | PDE5A (0.44) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL20161260 | 0.86 | PDE5A (0.44) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14776861 | 0.79 | GUCY1A1 (0.34) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14776630 | 0.76 | PDE5A (0.49) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL10071129 | 0.73 | GUCY1A1 (0.42) | GUCY1A1GUCY1B1 | |
| SCHEMBL16687380 | 0.73 | PDE5A (0.46) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL16687379 | 0.73 | PDE5A (0.49) | PDE5AGUCY1A1GUCY1B1 | |
| Hydrochloric Acid SCHEMBL20140172 | 0.72 | GUCY1A1 (0.41) | GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| WO-2025016393-A1 | 4-AMINO-PYRROLO[2,3-D]PYRIMIDIN-6-ONE DERIVATIVE AND USE THEREOF IN MEDICINE | 海思科医药集团股份有限公司 | 2025-01-23 | — | — | WO | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| CN-108738320-B | cGMP modulators for the treatment of cardiovascular diseases | 默沙东公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3394067-B1 | 4-AMINO-2-(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-6-OXO-6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL) DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-3394067-B1 | 4-AMINO-2-(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-6-OXO-6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL) DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
| US-9365574-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2575473-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9023849-B2 | Substituted fused imidazoles and pyrazoles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| EP-2802587-A2 | SUBSTITUTED, ANNULATED IMIDAZOLES AND PYRAZOLES, AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-20130210824-A1 | Substituted fused imidazoles and pyrazoles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| WO-2013104598-A2 | SUBSTITUTED, ANNULATED IMIDAZOLES AND PYRAZOLES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-18 | — | — | WO | disclosed |
| EP-2575473-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-03-21 | — | — | US | disclosed |
| WO-2011149921-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | PDE5A 12/4885GUCY1A1 4/4885GUCY1B1 6/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | PDE5A 12/4885GUCY1A1 4/4885GUCY1B1 6/4885 |
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE2A | PDE5A 7/4885GUCY1A1 2/4885GUCY1B1 8/4885 |
| US-20130210824-A1 | Substituted fused imidazoles and pyrazoles and use thereof | CYP4F3, CYP11B2, CYP4F2 | PDE5A 566/4885GUCY1A1 2458/4885GUCY1B1 1255/4885 |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A1, GUCY1A2, PDE2A | PDE5A 8/4885GUCY1A1 1/4885GUCY1B1 4/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | PDE5A 12/4885GUCY1A1 4/4885GUCY1B1 6/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | PDE5A 12/4885GUCY1A1 4/4885GUCY1B1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.